Tirzepatide vs Montelukast: side-by-side comparison
Tirzepatide (GIP/GLP-1 dual receptor agonist) and Montelukast (Leukotriene receptor antagonist) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Tirzepatide | Montelukast |
|---|---|---|
| Therapeutic class | GIP/GLP-1 dual receptor agonist | Leukotriene receptor antagonist |
| CAS | 2023788-19-2 | 158966-92-8 |
| ATC | A10BX16 | R03DC03 |
| Molecular weight | 4813.5 g/mol | 586.18 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Tirzepatide and Montelukast share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Tirzepatide acts by a different mechanism than Montelukast, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Tirzepatide: Tirzepatide binds with high affinity to the GIP receptor and to the GLP-1 receptor. Montelukast: Montelukast selectively blocks the CysLT1 receptor, which mediates the action of leukotrienes C4, D4 and E4 — proinflammatory mediators released by mast cells and eosinophils in the airway.
Indications compared
Tirzepatide: Tirzepatide is approved in adults with type 2 diabetes mellitus, as monotherapy or in combination with other antidiabetic agents, to improve glycaemic control. Montelukast: Montelukast is approved in adults and children for the maintenance treatment of asthma, including exercise-induced bronchospasm, and for the treatment of seasonal and perennial allergic rhinitis when conventional therapy…
Safety profile
Tirzepatide: The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, decreased appetite, constipation and abdominal discomfort, generally mild to moderate and most pronounced during dose escalation. Montelukast: Common adverse effects include headache, gastrointestinal symptoms and upper respiratory tract infection.
Frequently asked questions
Is Tirzepatide better than Montelukast? ▾
Tirzepatide and Montelukast are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Tirzepatide and Montelukast be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Tirzepatide
Products with Montelukast
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.